Latest news with #AshleyCordova
Business Wire
27-05-2025
- Business
- Business Wire
Novocure Announces Upcoming Investor Events
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. : Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership will be joined by Vincent Picozzi, MD, MMM, medical oncologist and investigator in the PANOVA-3 trial, to review the results and address questions. To request in-person attendance, please contact investor relations at investorinfo@ Jefferies Global Healthcare Conference, June 4, 2025: Ashley Cordova, Chief Executive Officer, will present on behalf of the company and address questions on June 4 at 12:50 p.m. ET. Ms. Cordova will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings with investors throughout the conference. Live audio webcasts of these presentations can be accessed from the Investor Relations page of Novocure's website, and will be available for replay for at least 14 days following the event. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure's global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe' or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Yahoo
24-04-2025
- Business
- Yahoo
Why NovoCure Stock Leaped 4% Higher Today
Thursday morning NovoCure (NASDAQ: NVCR) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index. For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow its generally accepted accounting principles (GAAP) net loss by roughly the same percentage; it landed at $34.4 million ($0.31 per share) against the Q1 2024 shortfall of $38.8 million. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » As a group, analysts tracking NovoCure's fortunes weren't expecting the company to do so well. Their collective estimate for net revenue was under $148 million; for headline net loss it was $0.49 per share. Although NovoCure is one of a big clutch of biotechs developing cancer therapies, it's unique in the segment. Its money technology is tumor treating fields (TTFs), which as the name suggests are electrical fields produced by a small device powered by a battery. These fields hold the promise of treating various cancers without the often heavy side effects of other therapies. NovoCure is also making a concentrated effort to branch out, an effort that's clearly appreciated by the market. It quoted CEO Ashley Cordova as saying that "our footprint is expanding across new indications, new centers, and new physician specialties." I'm not sure TTFs will become the go-to oncology treatment in the market, but the technology sure is intriguing and well worth watching. NovoCure stock is worth considering on that basis, in my view. Before you buy stock in NovoCure, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and NovoCure wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $566,035!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $629,519!* Now, it's worth noting Stock Advisor's total average return is 829% — a market-crushing outperformance compared to 155% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 21, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure. The Motley Fool has a disclosure policy. Why NovoCure Stock Leaped 4% Higher Today was originally published by The Motley Fool Sign in to access your portfolio
